Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | 5-ARIs impact prostate cancer outcomes due to delayed diagnosis

James Kearns, MD, University of North Carolina School of Medicine, Chapel Hill, NC, gives an outline of the impact of 5-alpha-reductase inhibitors (5-ARIs) on prostate cancer outcomes. 5-ARIs are often used to treat lower urinary tract symptoms caused by benign prostatic hyperplasia and previous research has suggested that 5-ARI use is associated with worse prostate cancer outcomes. 5-ARIs decrease the level of prostate-specific antigen (PSA) by up to 50% making prostate cancer harder to detect and delaying diagnosis. In particular, Dr Kearns discusses the results of a retrospective cohort study investigating the impact of 5-ARI use on prostate cancer risk at the time of referral from primary care to urology. Data from 91,368 men was analyzed, including data from 2,939 5-ARI users. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.